EA201690785A1 - Новая комбинированная терапия острого миелоидного лейкоза (омл) - Google Patents

Новая комбинированная терапия острого миелоидного лейкоза (омл)

Info

Publication number
EA201690785A1
EA201690785A1 EA201690785A EA201690785A EA201690785A1 EA 201690785 A1 EA201690785 A1 EA 201690785A1 EA 201690785 A EA201690785 A EA 201690785A EA 201690785 A EA201690785 A EA 201690785A EA 201690785 A1 EA201690785 A1 EA 201690785A1
Authority
EA
Eurasian Patent Office
Prior art keywords
aml
myeloid leukemia
acute myeloid
combined therapy
new combined
Prior art date
Application number
EA201690785A
Other languages
English (en)
Inventor
Брайан Хиггинс
Кэтрин Е. Пэкмен
Гвен Николс
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52014047&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201690785(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of EA201690785A1 publication Critical patent/EA201690785A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

Данное изобретение относится к фармацевтическому продукту, содержащему: а) в качестве первого компонента ингибитор взаимодействия MDM2-p53 и б) в качестве второго компонента цитарабин в виде комбинированного препарата для последовательного или одновременного применения при лечении рака, в частности ОМЛ.
EA201690785A 2013-12-05 2014-12-01 Новая комбинированная терапия острого миелоидного лейкоза (омл) EA201690785A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361912152P 2013-12-05 2013-12-05
PCT/EP2014/076063 WO2015082384A1 (en) 2013-12-05 2014-12-01 Novel combination treatment for acute myeloid leukemia (aml)

Publications (1)

Publication Number Publication Date
EA201690785A1 true EA201690785A1 (ru) 2016-10-31

Family

ID=52014047

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690785A EA201690785A1 (ru) 2013-12-05 2014-12-01 Новая комбинированная терапия острого миелоидного лейкоза (омл)

Country Status (31)

Country Link
US (5) US20160303158A1 (ru)
EP (1) EP3077004B1 (ru)
JP (3) JP6297695B2 (ru)
KR (1) KR101862955B1 (ru)
CN (1) CN105792847B (ru)
AR (1) AR098576A1 (ru)
AU (1) AU2014359422B2 (ru)
BR (1) BR112016009669B1 (ru)
CA (1) CA2926307C (ru)
CL (1) CL2016001345A1 (ru)
CR (1) CR20160173A (ru)
DK (1) DK3077004T3 (ru)
EA (1) EA201690785A1 (ru)
ES (1) ES2785203T3 (ru)
HK (1) HK1222808A1 (ru)
HR (1) HRP20200566T1 (ru)
HU (1) HUE049434T2 (ru)
IL (1) IL244888B (ru)
LT (1) LT3077004T (ru)
MA (1) MA39040A1 (ru)
MX (1) MX370618B (ru)
PE (1) PE20160591A1 (ru)
PH (1) PH12016500933A1 (ru)
PL (1) PL3077004T3 (ru)
PT (1) PT3077004T (ru)
RS (1) RS60142B1 (ru)
SG (1) SG11201604504VA (ru)
SI (1) SI3077004T1 (ru)
TW (2) TWI678204B (ru)
WO (1) WO2015082384A1 (ru)
ZA (1) ZA201602829B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101623985B1 (ko) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
CA2807685C (en) 2010-08-13 2020-10-06 Aileron Therapeutics, Inc. P53 derived peptidomimetic macrocycle
JP6342808B2 (ja) 2011-10-18 2018-06-13 エイルロン セラピューティクス，インコーポレイテッド ペプチドミメティック大環状化合物
CA2887285A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
JP6297695B2 (ja) * 2013-12-05 2018-03-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 急性骨髄性白血病（ａｍｌ）のための新規併用治療
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
CN112245565A (zh) 2014-09-24 2021-01-22 艾瑞朗医疗公司 拟肽大环化合物及其用途
SG11201702175YA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
EP3344275B8 (en) * 2015-09-03 2023-04-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
SG11201809501PA (en) * 2016-06-06 2018-12-28 Celgene Corp Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
JP6848047B2 (ja) * 2016-08-08 2021-03-24 フェイ シアオ， スピロインドロンポリエチレングリコールカーボネート系化合物及びその組成物、調製方法及びその使用
CN109982702A (zh) 2016-11-15 2019-07-05 诺华股份有限公司 HDM2-p53相互作用抑制剂的剂量及方案
US20200281925A1 (en) * 2017-03-31 2020-09-10 Novartis Ag Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3858361A4 (en) 2018-09-28 2021-12-01 FUJIFILM Corporation ANTITUMOR AGENT CONTAINING CYTARABINE, ANTITUMOR ACTIVATOR USED IN COMBINATION WITH CYTARABINE, ANTITUMOR KIT, AND ANTITUMOR AGENT USED IN COMBINATION WITH CYTARABINE
JP2022501394A (ja) * 2019-07-26 2022-01-06 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド Ｍｄｍ２阻害剤の医薬組成物、並びに疾患を予防及び／又は治療するためのその使用
KR20240032732A (ko) * 2021-05-13 2024-03-12 엔카르타, 인크. 암 면역요법을 위한 투약 요법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE381332T1 (de) * 2002-05-02 2008-01-15 Merck & Co Inc Tyrosinkinase-hemmer
DE102005012681A1 (de) * 2005-03-18 2006-09-21 Weber, Lutz, Dr. Neue 1,5-Dihydro-pyrrol-2-one
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CN101773408B (zh) * 2010-01-15 2012-04-04 平荧 多功能排针结合电凝固技术提升下垂皮肤的装置
CA2800519A1 (en) * 2010-04-09 2011-10-13 The Regents Of The University Of Michigan Biomarkers for mdm2 inhibitors for use in treating disease
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US20120010235A1 (en) * 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
US8993614B2 (en) * 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
JP6297695B2 (ja) * 2013-12-05 2018-03-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 急性骨髄性白血病（ａｍｌ）のための新規併用治療
US9657351B2 (en) * 2013-12-06 2017-05-23 Hoffman-La Roche Inc. MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist

Also Published As

Publication number Publication date
CA2926307A1 (en) 2015-06-11
ZA201602829B (en) 2017-04-26
US20200253999A1 (en) 2020-08-13
MX2016007170A (es) 2016-09-08
PT3077004T (pt) 2020-04-16
US20160303158A1 (en) 2016-10-20
CL2016001345A1 (es) 2017-04-07
RS60142B1 (sr) 2020-05-29
CR20160173A (es) 2016-06-08
EP3077004A1 (en) 2016-10-12
MX370618B (es) 2019-12-17
US20220031726A1 (en) 2022-02-03
EP3077004B1 (en) 2020-02-19
JP6297695B2 (ja) 2018-03-20
JP2018111700A (ja) 2018-07-19
SG11201604504VA (en) 2016-07-28
ES2785203T3 (es) 2020-10-06
IL244888A0 (en) 2016-05-31
WO2015082384A1 (en) 2015-06-11
CA2926307C (en) 2021-11-16
AU2014359422B2 (en) 2020-03-05
TWI678204B (zh) 2019-12-01
AU2014359422A1 (en) 2016-04-28
JP6918724B2 (ja) 2021-08-11
TW201840310A (zh) 2018-11-16
DK3077004T3 (da) 2020-04-27
SI3077004T1 (sl) 2020-07-31
PL3077004T3 (pl) 2020-08-10
CN105792847A (zh) 2016-07-20
BR112016009669B1 (pt) 2023-01-24
US20230381215A1 (en) 2023-11-30
PE20160591A1 (es) 2016-06-11
LT3077004T (lt) 2020-05-11
KR101862955B1 (ko) 2018-05-31
AR098576A1 (es) 2016-06-01
BR112016009669A8 (pt) 2020-04-07
KR20160070190A (ko) 2016-06-17
JP2016539160A (ja) 2016-12-15
HUE049434T2 (hu) 2020-09-28
US20150157603A1 (en) 2015-06-11
JP2021091690A (ja) 2021-06-17
CN105792847B (zh) 2019-11-08
IL244888B (en) 2020-11-30
MA39040A1 (fr) 2018-01-31
PH12016500933A1 (en) 2016-06-27
TW201526890A (zh) 2015-07-16
HK1222808A1 (zh) 2017-07-14
HRP20200566T1 (hr) 2020-06-26
TWI627954B (zh) 2018-07-01
US9956243B2 (en) 2018-05-01

Similar Documents

Publication Publication Date Title
EA201690785A1 (ru) Новая комбинированная терапия острого миелоидного лейкоза (омл)
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
EA202092456A2 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
EA201890204A1 (ru) Антибактериальные соединения
EA201590987A1 (ru) Соединения и способы их применения
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
MY186311A (en) Bicyclic heterocycle compounds and their uses in therapy
EA201500314A1 (ru) Лекарственные формы энзалутамида
EA201491447A1 (ru) Ендиины, их конъюгаты и способы их получения и применения
EA201691155A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
EA201590997A1 (ru) Соединения и способы их применения
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
EA201690898A1 (ru) Способы лечения таупатии
WO2015009726A3 (en) Medical uses of cd38 agonists
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
EA201501187A1 (ru) Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
EA201691570A1 (ru) Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента
EA201600288A1 (ru) Замещенные фенилаланиновые производные